Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2011 Aug;60(2):205-10.
doi: 10.1016/j.eururo.2011.03.011. Epub 2011 Mar 21.

Salvage radical prostatectomy for radiation-recurrent prostate cancer: a multi-institutional collaboration

Daher C Chade  1 , Shahrokh F Shariat, Angel M Cronin, Caroline J Savage, R Jeffrey Karnes, Michael L Blute, Alberto Briganti, Francesco Montorsi, Henk G van der Poel, Hendrik Van Poppel, Steven Joniau, Guilherme Godoy, Antonio Hurtado-Coll, Martin E Gleave, Marcos Dall'Oglio, Miguel Srougi, Peter T Scardino, James A Eastham
Affiliations
Multicenter Study

Salvage radical prostatectomy for radiation-recurrent prostate cancer: a multi-institutional collaboration

Daher C Chade et al. Eur Urol. 2011 Aug.

Abstract

Background: Oncologic outcomes in men with radiation-recurrent prostate cancer (PCa) treated with salvage radical prostatectomy (SRP) are poorly defined.

Objective: To identify predictors of biochemical recurrence (BCR), metastasis, and death following SRP to help select patients who may benefit from SRP.

Design, setting, and participants: This is a retrospective, international, multi-institutional cohort analysis. There was a median follow-up of 4.4 yr following SRP performed on 404 men with radiation-recurrent PCa from 1985 to 2009 in tertiary centers.

Intervention: Open SRP.

Measurements: BCR after SRP was defined as a serum prostate-specific antigen (PSA) ≥ 0.1 or ≥ 0.2 ng/ml (depending on the institution). Secondary end points included progression to metastasis and cancer-specific death.

Results and limitations: Median age at SRP was 65 yr of age, and median pre-SRP PSA was 4.5 ng/ml. Following SRP, 195 patients experienced BCR, 64 developed metastases, and 40 died from PCa. At 10 yr after SRP, BCR-free survival, metastasis-free survival, and cancer-specific survival (CSS) probabilities were 37% (95% confidence interval [CI], 31-43), 77% (95% CI, 71-82), and 83% (95% CI, 76-88), respectively. On preoperative multivariable analysis, pre-SRP PSA and Gleason score at postradiation prostate biopsy predicted BCR (p = 0.022; global p < 0.001) and metastasis (p = 0.022; global p < 0.001). On postoperative multivariable analysis, pre-SRP PSA and pathologic Gleason score at SRP predicted BCR (p = 0.014; global p < 0.001) and metastasis (p < 0.001; global p < 0.001). Lymph node involvement (LNI) also predicted metastasis (p = 0.017). The main limitations of this study are its retrospective design and the follow-up period.

Conclusions: In a select group of patients who underwent SRP for radiation-recurrent PCa, freedom from clinical metastasis was observed in >75% of patients 10 yr after surgery. Patients with lower pre-SRP PSA levels and lower postradiation prostate biopsy Gleason score have the highest probability of cure from SRP.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Kaplan-Meier curves reflecting proportion of patients free from (a, d) biochemical recurrence, (b) metastasis, and (c) prostate cancer–specific death following salvage radical prostatectomy (SRP). (d) Low-risk subpopulation (n = 93; pre-SRP prostate-specific antigen ≤4 ng/ml and pre-SRP biopsy Gleason score ≤7). Dashed lines indicate 95% confidence intervals.
Fig. 1
Fig. 1
Kaplan-Meier curves reflecting proportion of patients free from (a, d) biochemical recurrence, (b) metastasis, and (c) prostate cancer–specific death following salvage radical prostatectomy (SRP). (d) Low-risk subpopulation (n = 93; pre-SRP prostate-specific antigen ≤4 ng/ml and pre-SRP biopsy Gleason score ≤7). Dashed lines indicate 95% confidence intervals.
Fig. 1
Fig. 1
Kaplan-Meier curves reflecting proportion of patients free from (a, d) biochemical recurrence, (b) metastasis, and (c) prostate cancer–specific death following salvage radical prostatectomy (SRP). (d) Low-risk subpopulation (n = 93; pre-SRP prostate-specific antigen ≤4 ng/ml and pre-SRP biopsy Gleason score ≤7). Dashed lines indicate 95% confidence intervals.
Fig. 1
Fig. 1
Kaplan-Meier curves reflecting proportion of patients free from (a, d) biochemical recurrence, (b) metastasis, and (c) prostate cancer–specific death following salvage radical prostatectomy (SRP). (d) Low-risk subpopulation (n = 93; pre-SRP prostate-specific antigen ≤4 ng/ml and pre-SRP biopsy Gleason score ≤7). Dashed lines indicate 95% confidence intervals.
See this image and copyright information in PMC

Comment in

References

    1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277–300. - PubMed
    1. Zietman AL, Bae K, Slater JD, et al. Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from Proton Radiation Oncology Group/American College of Radiology 95-09. J Clin Oncol. 2010;28:1106–11. - PMC - PubMed
    1. Zelefsky MJ, Eastham JA, Cronin AM, et al. Metastasis after radical prostatectomy or external beam radiotherapy for patients with clinically localized prostate cancer: a comparison of clinical cohorts adjusted for case mix. J Clin Oncol. 2010;28:1508–13. - PMC - PubMed
    1. D’Amico AV, Chen MH, Renshaw AA, Loffredo M, Kantoff PW. Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. JAMA. 2008;299:289–95. - PubMed
    1. Lee WR, Hanks GE, Hanlon A. Increasing prostate-specific antigen profile following definitive radiation therapy for localized prostate cancer: clinical observations. J Clin Oncol. 1997;15:230–8. - PubMed

Publication types

MeSH terms

Substances